Form 4: RA Capital Director Receives Tyra Biosciences Option Grant

RA Capital Management reports a stock option grant for director Dr. Jake Simson under the Tyra Biosciences non-employee director compensation program.

Summary

• Dr. Jake Simson, a partner at RA Capital Management, was granted an option to purchase 13,160 shares of Tyra Biosciences common stock.
• The grant was issued on May 28, 2026, with an exercise price of $32.68 per share.
• The options vest monthly over 12 months, with provisions for full vesting upon the next annual stockholder meeting if it occurs before the first anniversary.
• The reporting persons (RA Capital entities and principals) disclaim beneficial ownership of these options, as they are held for the benefit of the funds managed by the Adviser.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized compensation structure under the Issuer's Non-Employee Director Compensation Program.

Negatives

• None identified; this is a routine compensatory disclosure.

Risks

• Market price volatility of Tyra Biosciences common stock could impact the future value of the granted options.
• Vesting is contingent upon Dr. Jake Simson's continuous service to the issuer.

Future Outlook

The options vest monthly over a one-year period, with an expiration date of May 27, 2036.

Management Comments

• The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

StockSavvy.ai notes that equity grants to board members from major institutional investors like RA Capital are standard practice in the biotech sector to ensure board alignment with corporate strategy.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation in the biotechnology sector.
• The use of a 12-month vesting schedule is consistent with typical board compensation packages for small-to-mid-cap life sciences companies.

Corporate Governance

Related Party Transactions

• Dr. Jake Simson holds the option for the benefit of RA Capital funds, with proceeds offset against advisory fees.

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.
• Employees: No direct impact.

Next Steps

• Monthly vesting of options beginning after May 28, 2026.
• Potential full vesting at the next annual meeting of stockholders.

Key Dates

Keywords

Tyra Biosciences, TYRA, RA Capital Management, Form 4, Director Compensation, Stock Options, Insider Ownership